FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068828048> ?p ?o ?g. }

• W2068828048 endingPage "2115" @default.
• W2068828048 startingPage "2107" @default.
• W2068828048 abstract "Background Radiation dose escalation within definitive radiochemotherapy (RTx/CTx) was not successful for stage III non-small cell lung cancer (NSCLC) using conventional fractionation (CF). Accelerated-hyperfractionation (AHF) counteracts tumour cell repopulation. In this observational study, the effects of neoadjuvant RTx/CTx using AHF or CF were studied by histopathology and using the survival end-point. Methods Data from all consecutive lung cancer patients treated with neoadjuvant RTx/CTx and thoracotomy between 08/2000 and 06/2012 were analysed. Patients received induction chemotherapy (cisplatin-doublets) followed by concurrent RTx/CTx using AHF (45 Gy/1.5 Gy bid) or CF-RTx (46 Gy/2 Gy qd). For estimating the AHF versus CF treatment effects, multivariate analysis (MA), propensity score weighting (PS), and instrumental variable analysis (IV) were used. Findings 239 patients were treated, median age 58 (34–78) years, stage II/IIIA/B: 19/88/132, squamous cell/adenocarcinomas/other: 98/107/34; AHF/CF-RTx 112/127 patients. No significant differences between both groups, in tumour related factors (age, gender, Charlson comorbiditiy score, lactate dehydrogenase (LDH), haemoglobin, stage, histopathology and grading), existed. Crude rates of pathologic complete responses (pCR) in AHF and CF groups were 37% and 24% respectively. The dose fractionation effect on pCR was significant (p ⩽ 0·006, PS and IV analyses). There was a significant dependence of pCR on biologically effective dose. pCR also depended on treatment time (MA, p = 0·04; PS, p = 0·0004). Median treatment time was 22 d or 31 d using AHF or CF (p < 0.0001), respectively. Adenocarcinomas had lower pCR rates in comparison to other histologies. Five-year survival of patients with pCR was 65%, independent of the fractionation. Interpretation This large monoinstitutional analysis demonstrates an increased effect of AHF on pCR of lung cancer which modifies overall survival." @default.
• W2068828048 created "2016-06-24" @default.
• W2068828048 creator A5001668405 @default.
• W2068828048 creator A5023794918 @default.
• W2068828048 creator A5025476854 @default.
• W2068828048 creator A5034451063 @default.
• W2068828048 creator A5040777787 @default.
• W2068828048 creator A5043479866 @default.
• W2068828048 creator A5047006205 @default.
• W2068828048 creator A5070751347 @default.
• W2068828048 creator A5071494218 @default.
• W2068828048 creator A5071766547 @default.
• W2068828048 creator A5075237269 @default.
• W2068828048 date "2013-06-01" @default.
• W2068828048 modified "2023-09-26" @default.
• W2068828048 title "Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation" @default.
• W2068828048 cites W1954745527 @default.
• W2068828048 cites W1967593563 @default.
• W2068828048 cites W1986817993 @default.
• W2068828048 cites W1999058743 @default.
• W2068828048 cites W2003456733 @default.
• W2068828048 cites W2022693950 @default.
• W2068828048 cites W2023225613 @default.
• W2068828048 cites W2025194893 @default.
• W2068828048 cites W2025560151 @default.
• W2068828048 cites W2041752578 @default.
• W2068828048 cites W2044673415 @default.
• W2068828048 cites W2051955621 @default.
• W2068828048 cites W2058693420 @default.
• W2068828048 cites W2059149151 @default.
• W2068828048 cites W2063247340 @default.
• W2068828048 cites W2065486931 @default.
• W2068828048 cites W2069787198 @default.
• W2068828048 cites W2077910495 @default.
• W2068828048 cites W2094970178 @default.
• W2068828048 cites W2103079507 @default.
• W2068828048 cites W2104134194 @default.
• W2068828048 cites W2104701073 @default.
• W2068828048 cites W2110996227 @default.
• W2068828048 cites W2112749052 @default.
• W2068828048 cites W2117032294 @default.
• W2068828048 cites W2122532950 @default.
• W2068828048 cites W2151020778 @default.
• W2068828048 cites W2155743116 @default.
• W2068828048 cites W2159746573 @default.
• W2068828048 cites W2326531429 @default.
• W2068828048 cites W2590835098 @default.
• W2068828048 doi "https://doi.org/10.1016/j.ejca.2013.02.030" @default.
• W2068828048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23510803" @default.
• W2068828048 hasPublicationYear "2013" @default.
• W2068828048 type Work @default.
• W2068828048 sameAs 2068828048 @default.
• W2068828048 citedByCount "12" @default.
• W2068828048 countsByYear W20688280482014 @default.
• W2068828048 countsByYear W20688280482015 @default.
• W2068828048 countsByYear W20688280482017 @default.
• W2068828048 countsByYear W20688280482019 @default.
• W2068828048 countsByYear W20688280482021 @default.
• W2068828048 countsByYear W20688280482022 @default.
• W2068828048 crossrefType "journal-article" @default.
• W2068828048 hasAuthorship W2068828048A5001668405 @default.
• W2068828048 hasAuthorship W2068828048A5023794918 @default.
• W2068828048 hasAuthorship W2068828048A5025476854 @default.
• W2068828048 hasAuthorship W2068828048A5034451063 @default.
• W2068828048 hasAuthorship W2068828048A5040777787 @default.
• W2068828048 hasAuthorship W2068828048A5043479866 @default.
• W2068828048 hasAuthorship W2068828048A5047006205 @default.
• W2068828048 hasAuthorship W2068828048A5070751347 @default.
• W2068828048 hasAuthorship W2068828048A5071494218 @default.
• W2068828048 hasAuthorship W2068828048A5071766547 @default.
• W2068828048 hasAuthorship W2068828048A5075237269 @default.
• W2068828048 hasConcept C126322002 @default.
• W2068828048 hasConcept C126894567 @default.
• W2068828048 hasConcept C142724271 @default.
• W2068828048 hasConcept C143998085 @default.
• W2068828048 hasConcept C146357865 @default.
• W2068828048 hasConcept C151730666 @default.
• W2068828048 hasConcept C2776256026 @default.
• W2068828048 hasConcept C2776694085 @default.
• W2068828048 hasConcept C509974204 @default.
• W2068828048 hasConcept C544855455 @default.
• W2068828048 hasConcept C71924100 @default.
• W2068828048 hasConcept C86803240 @default.
• W2068828048 hasConcept C90924648 @default.
• W2068828048 hasConceptScore W2068828048C126322002 @default.
• W2068828048 hasConceptScore W2068828048C126894567 @default.
• W2068828048 hasConceptScore W2068828048C142724271 @default.
• W2068828048 hasConceptScore W2068828048C143998085 @default.
• W2068828048 hasConceptScore W2068828048C146357865 @default.
• W2068828048 hasConceptScore W2068828048C151730666 @default.
• W2068828048 hasConceptScore W2068828048C2776256026 @default.
• W2068828048 hasConceptScore W2068828048C2776694085 @default.
• W2068828048 hasConceptScore W2068828048C509974204 @default.
• W2068828048 hasConceptScore W2068828048C544855455 @default.
• W2068828048 hasConceptScore W2068828048C71924100 @default.
• W2068828048 hasConceptScore W2068828048C86803240 @default.
• W2068828048 hasConceptScore W2068828048C90924648 @default.
• W2068828048 hasIssue "9" @default.

• next